Moreover, a recent study showed that C66 predominantly targeted JNK2, as both Jnk2 gene deletion and C66 treatment could similarly activate NRF2 and alleviate diabetes‐induced aortic oxidative stress, inflammation and fibrosis.43 This evidence concerns the gene MAPK9 and diabetes mellitus.